The tested peptidomimetics are stable in human plasma and serum for at least 10 days, suggesting that these TMPRSS2 inhibitors are promising leads for further development as antiviral drugs in COVID-19 therapy and other viral diseases. Here, TMPRSS2 is linked to COVID-19.